50, Park Plz

Boston,

MA,

USA,

ZIP: 02116

Phone: + 1 617 455 4188

The 2nd LNP Immunogenicity and Toxicity Summit is set to unite 100+ PKPD, Immunology, Safety, Toxicology experts from biopharma and academia. This is your opportunity to join key opinion leaders within the industry to explore the steep progress being made in the space and actively address the field's most pressing challenges through multiple deep-dive discussions.

In collaboration with Pfizer, BioNTech, Sanofi and Eli Lilly, this 3-day summit will bring together senior leaders dedicated to understanding and predicting the next wave of LNP's immunogenicity and toxicity challenges, to support drug developers to ensure smooth filing with long-term patient safety in mind.

This year we are moving alongside the pharmaceutical industry and bringing the focus to accurately measuring immuno-tox of their LNP for regulatory IND filing, using different payloads in LNPs beyond mRNA and understanding the importance of accurate immunogenicity and toxicity studies for approval and patient safety.

Do not miss out on the only industry forum dedicated to uncovering immunogenicity and toxicity challenges within the LNP space and takeaway:

- Robust analysis of LNPs to unpick driving factors behind immune response and immune cell engagement
- Preclinical models from in vitro, animal models and 3D tissue models to optimize translatability into the clinic
- Understanding of LNP immunogenicity and toxicity read-outs in relation to application of vaccine, gene therapy and chronic disease
- Advanced immunogenicity models to minimize anti-PEG response, and PEG alternatives to minimize adverse effects
- Widened therapeutic windows and well understood dose limiting toxicities for maximal efficacious benefit
- Evaluation of the LNP-payload complex beyond mRNA for next-generation development

Group discounts and early bird rates are available - please visit the website for more info.


URLs:
Tickets: https://go.evvnt.com/1900575-1?pid=1052
Brochure: https://go.evvnt.com/1900575-3?pid=1052
LinkedIn: https://go.evvnt.com/1900575-4?pid=1052

Prices:
Full Access Pass (Conference + Workshop Day) - Drug Developer Pricing: USD 5046.00,
Conference Only - Drug Developer Pricing: USD 3099.00,
Full Access Pass (Conference + Workshop Day) - Academic Pricing: USD 4246.00,
Conference Only - Academic Pricing: USD 2599.00,
Full Access Pass (Conference + Workshop Day) - Service Provider Pricing: USD 6046.00,
Conference Only - Service Provider Pricing: USD 3799.00

Amy Rosenberg, Senior Director of Immunology and Protein Therapeutics, Epivax, Daryl Drummond, Chief Scientific Officer, Akagera Medicines, Esmaiel Jabbari, Professor of Chemical and Biomedical Engineering, University of South Carolina, Hicham Alaoui, Chief Scientific Officer General, Glycomine, Jake Brenner, Associate Director and Assistant Professor - Medicine, University of Pennsylvania, Jan Diekmann, Senior Director Non-clinical Safety, BioNTech, Jian Lu Chief, Scientist Director of Toxicology, Nitto BioPharma, Joanna Grudzinska, Drug Metabolism and Pharmacokinetics Project Manager, Bayer AG, Julien Couture-Senecal, Teaching Assistant, University of Toronto, Lisa Plitnicky, Distinguished Scientist, Merck and Co, Maja Sedic, Director of Toxicology, ReNAgade Therapeutics, Maria Dolores Vazquez-Abad, Medicines Team Lead, Clinical Immunogenicity, Pfizer, Nick Weber, Principal Scientist, Vivet Therapeutics, Olga Lihoradova, Distinguished Scientist, Sanofi, Pedro Cejas, Head of New Therapeutic Modalities, Spark Therapeutics, Rakesh Dixit, President and Chief Executive Officer, Bionavigen, Rui Zhang, Director of Lipid Nanoparticles and Formulation, Stylus Medicine, Sophie Tourdot, Immunogenicity Sciences Lead, Pfizer, Virna Cortez-Retamozo, Head Of Group Onco-Pharmacology, Genzyme, Zohreh Amoozgar, Principal Scientist and Head of Lab, Sanofi